Publications by authors named "A Tieghi"
Article Synopsis
- Ruxolitinib (RUX) is a treatment for myelofibrosis, mainly studied in high-risk patients, but is often given to intermediate-1 patients with limited data on its effects.
- In a study of 1,055 myelofibrosis patients, over half were classified as intermediate-1 risk, with notable symptoms and some having high-molecular-risk mutations.
- The study found that after 6 months of RUX treatment, a significant proportion of patients experienced improvements in spleen size and symptoms, with certain factors like the absence of high-molecular-risk mutations being linked to better treatment responses.
Article Synopsis
- Anemia is common in patients with myelofibrosis (MF) and is worsened by the treatment drug ruxolitinib (RUX), with new cases of blast phase (BP) emerging in anemic patients not previously on this treatment.
- A study of 886 MF patients treated with RUX found a BP incidence rate of 3.74 per 100 patient-years, with higher rates in patients who had varying levels of anemia; the most severe cases were in those dependent on transfusions.
- The findings suggest that both pre-existing and treatment-induced anemia significantly increase the risk of BP development, indicating a need for better anemia treatments alongside MF therapies.
Article Synopsis
- A significant number of myelofibrosis patients stop using ruxolitinib within the first 5 years due to treatment failure, highlighting the need for early identification of those at risk.* -
- A study analyzed data from 889 patients and found that factors like low platelet count, low hemoglobin, and certain disease types increase the likelihood of stopping ruxolitinib treatment early.* -
- A new prognostic model called STR-PM was developed to categorize patients into low, intermediate, and high-risk groups for early treatment failure, suggesting that those in higher risk categories might benefit from alternative treatments.*
Background: Hematological malignancies (HMs) represent a heterogeneous group of diseases with diverse etiology, pathogenesis, and prognosis. HMs' accurate registration by Cancer Registries (CRs) is hampered by the progressive de-hospitalization of patients and the transition to molecular rather than microscopic diagnosis.
Material And Methods: A dedicated software capable of automatically identifying suspected HMs cases by combining several databases was adopted by Reggio Emilia Province CR (RE-CR).